INTRODUCTION: Histone deacetylases (HDACs) are enzymes involved in epigenetic modifications that shift the balance toward chromatin condensation and silencing of gene expression. Here, we evaluate the utility of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide ([(18)F]FAHA) for positron emission tomography imaging of HDAC activity in the baboon brain. For this purpose, we assessed its in vivo biodistribution, sensitivity to HDAC inhibition, metabolic stability and the distribution of the putative metabolite [(18)F]fluoroacetate ([(18)F]FAC). METHODS: [(18)F]FAHA and its metabolite [(18)F]FAC were prepared, and their in vivo biodistribution and pharmacokinetics were determined in baboons. [(18)F]FAHA metabolism and its sensitivity to HDAC inhibition using suberanilohydroxamic acid (SAHA) were assessed in arterial plasma and by in vitro incubation studies. The chemical form of F-18 in rodent brain was assessed by ex vivo studies. Distribution volumes for [(18)F]FAHA in the brain were derived. RESULTS: [(18)F]FAHA was rapidly metabolized to [(18)F]FAC, and both labeled compounds entered the brain. [(18)F]FAHA exhibited regional differences in brain uptake and kinetics. In contrast, [(18)F]FAC showed little variation in regional brain uptake and kinetics. A kinetic analysis that takes into account the uptake of peripherally produced [(18)F]FAC indicated that SAHA inhibited binding of [(18)F]FAHA in the baboon brain dose-dependently. In vitro studies demonstrated SAHA-sensitive metabolism of [(18)F]FAHA to [(18)F]FAC within the cell and diffusion of [(18)F]FAC out of the cell. All radioactivity in brain homogenate from rodents was [(18)F]FAC at 7 min postinjection of [(18)F]FAHA. CONCLUSION: The rapid metabolism of [(18)F]FAHA to [(18)F]FAC in the periphery complicates the quantitative analysis of HDAC in the brain. However, dose-dependent blocking studies with SAHA and kinetic modeling indicated that a specific interaction of [(18)F]FAHA in the brain was observed. Validating the nature of this interaction as HDAC specific will require additional studies.
INTRODUCTION: Histone deacetylases (HDACs) are enzymes involved in epigenetic modifications that shift the balance toward chromatin condensation and silencing of gene expression. Here, we evaluate the utility of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide ([(18)F]FAHA) for positron emission tomography imaging of HDAC activity in the baboon brain. For this purpose, we assessed its in vivo biodistribution, sensitivity to HDAC inhibition, metabolic stability and the distribution of the putative metabolite [(18)F]fluoroacetate ([(18)F]FAC). METHODS: [(18)F]FAHA and its metabolite [(18)F]FAC were prepared, and their in vivo biodistribution and pharmacokinetics were determined in baboons. [(18)F]FAHA metabolism and its sensitivity to HDAC inhibition using suberanilohydroxamic acid (SAHA) were assessed in arterial plasma and by in vitro incubation studies. The chemical form of F-18 in rodent brain was assessed by ex vivo studies. Distribution volumes for [(18)F]FAHA in the brain were derived. RESULTS: [(18)F]FAHA was rapidly metabolized to [(18)F]FAC, and both labeled compounds entered the brain. [(18)F]FAHA exhibited regional differences in brain uptake and kinetics. In contrast, [(18)F]FAC showed little variation in regional brain uptake and kinetics. A kinetic analysis that takes into account the uptake of peripherally produced [(18)F]FAC indicated that SAHA inhibited binding of [(18)F]FAHA in the baboon brain dose-dependently. In vitro studies demonstrated SAHA-sensitive metabolism of [(18)F]FAHA to [(18)F]FAC within the cell and diffusion of [(18)F]FAC out of the cell. All radioactivity in brain homogenate from rodents was [(18)F]FAC at 7 min postinjection of [(18)F]FAHA. CONCLUSION: The rapid metabolism of [(18)F]FAHA to [(18)F]FAC in the periphery complicates the quantitative analysis of HDAC in the brain. However, dose-dependent blocking studies with SAHA and kinetic modeling indicated that a specific interaction of [(18)F]FAHA in the brain was observed. Validating the nature of this interaction as HDAC specific will require additional studies.
Authors: Ron S Broide; Jeff M Redwine; Najla Aftahi; Warren Young; Floyd E Bloom; Christopher J Winrow Journal: J Mol Neurosci Date: 2007 Impact factor: 3.444
Authors: Datta E Ponde; Carmen S Dence; Nobuyuki Oyama; Joonyoung Kim; Yuan-Chuan Tai; Richard Laforest; Barry A Siegel; Michael J Welch Journal: J Nucl Med Date: 2007-03 Impact factor: 10.057
Authors: Brian M Zeglis; NagaVaraKishore Pillarsetty; Vadim Divilov; Ronald A Blasberg; Jason S Lewis Journal: Nucl Med Biol Date: 2011-03-03 Impact factor: 2.408
Authors: Wayland Tang; Sharon A Kuruvilla; Valentin Galitovskiy; Min-Liang Pan; Sergei A Grando; Jogeshwar Mukherjee Journal: Am J Nucl Med Mol Imaging Date: 2014-06-07
Authors: J Adam Hendricks; Edmund J Keliher; Brett Marinelli; Thomas Reiner; Ralph Weissleder; Ralph Mazitschek Journal: J Med Chem Date: 2011-07-18 Impact factor: 7.446
Authors: Hsin-Hsien Yeh; Mei Tian; Rainer Hinz; Daniel Young; Alexander Shavrin; Uday Mukhapadhyay; Leo G Flores; Julius Balatoni; Suren Soghomonyan; Hwan J Jeong; Ashutosh Pal; Rajesh Uthamanthil; James N Jackson; Ryuichi Nishii; Hiroshi Mizuma; Hirotaka Onoe; Shinya Kagawa; Tatsuya Higashi; Nobuyoshi Fukumitsu; Mian Alauddin; William Tong; Karl Herholz; Juri G Gelovani Journal: Neuroimage Date: 2012-09-17 Impact factor: 6.556
Authors: Yajie Wang; Yan-Ling Zhang; Krista Hennig; Jennifer P Gale; Yijia Hong; Anna Cha; Misha Riley; Florence Wagner; Stephen J Haggarty; Edward Holson; Jacob Hooker Journal: Epigenetics Date: 2013-06-11 Impact factor: 4.528
Authors: Young Jun Seo; Lisa Muench; Alicia Reid; Jinzhu Chen; Yeona Kang; Jacob M Hooker; Nora D Volkow; Joanna S Fowler; Sung Won Kim Journal: Bioorg Med Chem Lett Date: 2013-10-30 Impact factor: 2.823
Authors: Hsiao-Ying Wey; Changning Wang; Frederick A Schroeder; Jean Logan; Julie C Price; Jacob M Hooker Journal: ACS Chem Neurosci Date: 2015-03-25 Impact factor: 4.418